Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia.
about
Variation in the gene coding for the M5 muscarinic receptor (CHRM5) influences cigarette dose but is not associated with dependence to drugs of addiction: evidence from a prospective population based cohort study of young adultsPharmacotherapy of methamphetamine addiction: an updateDiscovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probeDiscovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatinsDiscovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaMuscarinic acetylcholine receptor subtype expression in avian vestibular hair cells, nerve terminals and ganglion cellsUltrasonic vocalizations induced by sex and amphetamine in M2, M4, M5 muscarinic and D2 dopamine receptor knockout mice.Differential regulation of primary afferent input to spinal cord by muscarinic receptor subtypes delineated using knockout miceSomatodendritic targeting of M5 muscarinic receptor in the rat ventral tegmental area: implications for mesolimbic dopamine transmissionCombined scopolamine and ethanol treatment results in a locomotor stimulant response suggestive of synergism that is not blocked by dopamine receptor antagonists.AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.M₅ muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice.Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens.Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.Functional M3 muscarinic acetylcholine receptors in mammalian heartsEffect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus.Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's DiseaseRole of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cuesLigand-based virtual screen for the discovery of novel M5 inhibitor chemotypesMuscarinic acetylcholine receptor binding affinities of pethidine analogs.Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one.Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists.African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addiction.Affective analgesia following muscarinic activation of the ventral tegmental area in ratsLesions of cholinergic pedunculopontine tegmental nucleus neurons fail to affect cocaine or heroin self-administration or conditioned place preference in rats.Increased amphetamine-induced locomotor activity, sensitization, and accumbal dopamine release in M5 muscarinic receptor knockout mice.M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's locationMuscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets.Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.Injecting eye-drops: a mini-review on the non-clinical use of tropicamide.Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.Early signal of diverted use of tropicamide eye drops in France.Ultrasonic vocalizations of adult male Foxp2-mutant mice: behavioral contexts of arousal and emotion.Muscarinic Control of Rostromedial Tegmental Nucleus GABA Neurons and Morphine-induced Locomotion.Microinjection of M(5) muscarinic receptor antisense oligonucleotide into VTA inhibits FosB expression in the NAc and the hippocampus of heroin sensitized rats.Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation.Molecular, cellular and circuit basis of cholinergic modulation of pain.
P2860
Q21283784-955B3DEB-87F1-4F74-AEF1-272D8484E2FCQ24648913-2F2ABF52-0C94-4C0C-B8C9-F451E15493BAQ28237300-3F925531-CD17-440F-9551-958C896CABB2Q28244789-753A7F4B-7EB0-4472-A838-614715D4D523Q28300950-F47F9EAF-D648-4727-8A9F-0804B503ECF8Q30459624-949FE153-6300-4C80-B0E0-43BA7ED3A69EQ30494760-9E4B5763-F9A0-427B-ADE3-1AA4135B6160Q30496544-BE97B2D3-1368-487E-85E8-FF9586E03589Q33619553-E4F7FCAD-561E-4D50-855A-A0E88ABE7230Q33683909-27C6B549-A2D0-47B1-A3D0-086BF6BCD1ABQ33800979-66CFBA9E-E05D-4AA7-9C73-2EC36F202A62Q34076241-22FD44D1-5077-459B-AD71-D2A7EE66F6E5Q34079321-D154E661-43C1-4D70-BA60-08120D2EBD92Q34480978-77AE30FE-9A20-4AC1-B686-08E650B45D46Q34552778-669D11DA-FEC7-4147-890D-5A90F437CEDBQ35047149-53C82301-43DA-4385-B7C5-EA07E1D2E4B3Q35205782-A6A9045D-9AB3-4CE8-B06F-D7125754C195Q35534556-807F3ACA-5351-45FF-A20F-3F282EF93F96Q35789730-D215A989-42B1-44A5-A9DB-B2DF23EE82C8Q35792661-16CDE2D8-1C41-4A9D-9A56-6E3EDC09FC52Q36098318-F075F5ED-32F2-4BEA-8E36-DE74DC4A0251Q36238735-39B4D20E-CAA7-42BC-90E6-65C64FDC97D7Q36350375-66536E10-2913-4A96-80F4-117703CCC730Q36912560-39223A3B-01F4-4E1D-9EE8-9D27D0365E8AQ37200655-3E22FE43-D35F-42F4-B793-C209D5892A5EQ37376567-98F09D20-E6FA-46E8-8048-220B70EE1786Q37499189-B6B65A7C-4377-4EA0-82D0-60DF54F90C67Q37539911-F081BCDB-64DB-492B-87FF-FC15673F73C0Q37603769-5A4C8840-4985-4A71-90D0-2F3731A49FB2Q37954379-00390FED-4893-45F6-94C3-AF177B06B00CQ38070176-504087B8-6F2E-4EE3-8DAA-91A3561838B6Q38555620-66CABE96-CFF3-4030-ADEA-F2A0E4950977Q38755530-8175BB9D-C7A3-4918-83B8-77AC907E2C34Q38851564-BD3ACB80-0B0D-4930-A338-F2DA0042361CQ38940500-C27AA557-34B9-46A2-83BD-C2DF363B6AC1Q38942880-A748E5E7-BC70-4018-AB18-F1E4FBB00B4BQ40846005-0E2B9176-FC36-4F42-AB2A-B1519DB09DB5Q40955806-F2A39C53-A409-449F-A59E-492AFA4BA176Q42556634-2E599EF9-4797-48FD-84A9-A234FEED2D01Q43061482-D08D3C7A-DBB1-4A94-B433-F7948702E956
P2860
Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@ast
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@en
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@nl
type
label
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@ast
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@en
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@nl
prefLabel
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@ast
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@en
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@nl
P2093
P2860
P356
P1476
Deletion of the M5 muscarinic ...... al but not morphine analgesia.
@en
P2093
Agustin Zapata
Alokesh Duttaroy
Anthony S Basile
Irina Fedorova
Jurgen Wess
Masahisa Yamada
Toni Shippenberg
Xiaoguang Liu
P2860
P304
11452-11457
P356
10.1073/PNAS.162371899
P407
P577
2002-08-01T00:00:00Z